)
Edge20 Feb 2026
Dollar General: The Rural Retailer Playbook
How Dollar General built a small-box empire across rural America, scaling value and convenience into one of retail's most durable business models.
Connect Biopharma
Connect Biopharma (CNTB) investor relations material
Connect Biopharma Oppenheimer 36th Annual Healthcare Life Sciences Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Oppenheimer 36th Annual Healthcare Life Sciences Conference summary26 Feb, 2026
Strategic focus and clinical development
Lead asset Rademikibart targets IL-4Rα and is positioned as a next-generation antibody for asthma and COPD, with completed studies in atopic dermatitis and chronic asthma.
Licensed to a partner in China, where Phase III atopic dermatitis is complete and a chronic asthma study is ongoing.
Two ongoing studies target acute exacerbations of asthma and COPD, aiming to address a large, underserved global market.
Rademikibart’s unique binding profile offers rapid onset and improved efficacy compared to existing biologics, with significant FEV1 improvements observed within 24 hours.
IV administration is being explored to further accelerate onset, with initial safety and PK data expected soon.
Market opportunity and differentiation
Acute exacerbations represent a major unmet need, with millions of ER visits annually and no approved biologics for acute treatment.
Rademikibart shows a differentiated mechanism, reducing eosinophil levels and enhancing beta-agonist response, unlike dupilumab.
Market research indicates 40-45% preference share for acute use among patients not on biologics, with 75% of clinicians likely to continue chronic use after acute administration.
Acute indication is expected to drive chronic market adoption, with no direct competition due to label restrictions on other biologics.
Peak sales for acute and chronic indications are forecasted at up to $5 billion globally, excluding additional indications.
Regulatory and commercial outlook
Acute studies are designed for rapid readout, with endpoints focused on FEV1 and treatment failure within two weeks.
Phase III for acute indications could be completed within a year, with two studies anticipated due to the novel nature of the indication.
Chronic indication may require only modest bridging studies, leveraging global and China Phase III data.
Cash runway extends into 2027, with significant milestones and royalties expected from China partnership.
Anticipated catalysts include IV pharmacology data, Phase II acute results midyear, and potential atopic dermatitis approval in China by Q3.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Connect Biopharma earnings date
Q4 202531 Mar, 2026
Connect Biopharma
Next Connect Biopharma earnings date
Q4 202531 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Connect Biopharma Holdings Ltd is a global, clinical-stage biopharmaceutical company focused on developing innovative therapies for chronic inflammatory diseases by leveraging its expertise in T cell biology. The company is advancing a pipeline of novel small molecules and biologics, targeting various conditions such as atopic dermatitis, ulcerative colitis, and chronic pruritus. These therapies aim to address significant unmet medical needs by modulating immune system responses. Connect Biopharma's approach combines a deep understanding of T cell-driven research with proprietary Immune Modulation Technology Platform, aiming to significantly reduce the discovery time and cost for new, effective treatments. The company is headquartered in San Diego, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage